{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-006090","form_type":"8-K","ticker":"TDOC","cik":"0001477449","company_name":"Teladoc Health, Inc.","filed_at":"2022-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.856125+00:00","generated_at":"2026-06-26T04:03:37.436261+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Teladoc Q1 net loss $6.67B on $6.6B goodwill impairment; cuts 2022 guidance","bullets":["Q1 revenue $565.4M (+25% YoY); net loss $6.67B due to $6.6B non-cash goodwill impairment ($41.11/sh).","Adjusted EBITDA $54.5M (-4% YoY); net loss per share $41.58 vs. $1.31 a year ago.","FY 2022 guidance revised: revenue $2.4-2.5B, adj. EBITDA $240-265M, net loss per share ($43.50)-($43.00).","D2C mental health hit by higher ad costs with lower yield; chronic condition sales cycles elongated.","Primary360 and stepped-care chronic programs launched on multiple new clients in Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-006090","json":"https://secwatch.observer/filing/0001558370-22-006090.json","markdown":"https://secwatch.observer/filing/0001558370-22-006090.md","text":"https://secwatch.observer/filing/0001558370-22-006090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477449/000155837022006090/0001558370-22-006090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477449/000155837022006090/tdoc-20220427x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T04:03:37.436261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}